

References

1. Miller, G. A., "The Magical Number Seven, Plus or Minus Two: Some Limits on Our Capacity for Processing Information," Psychological Review, 101(2):343-352, 1994.
2. Shiffrin, R. M., and R. M. Nosofsky, "Seven Plus or Minus Two: A Commentary On Capacity Limitations," Psychological Review, 101(2):357-361, 1994.
3. Allen, P. A., and L. C. Crozier, "Age and Ideal Chunk Size," Journal of Gerontology: Psychological Sciences, 47(1):47-51, 1992.
4. Food and Drug Administration, "Consumer Comprehension and Preference for Variations in the Proposed Over-the-Counter Drug Labeling Format," in OTC vol. 28FR, Docket No. 96N-0420, Dockets Management Branch.
5. National Surveys of Prescription Medicine Information Received by Consumers,
<http://www.fda.gov/cder/ddmac/y2ktable.htm>.
<http://www.fda.gov/dcer/ddmac/y2kTITLE.htm>.
6. Kripalani, S., "The Write Stuff: Simple Guidelines Can Help You Write and Design Effective

2000N-1269

BKG 2

24 Patient Education Materials," Texas Medicine, 91:40-
25 45, 1995.

26 7. Backinger, C. L., and P. A. Kingsley, "Write
27 It Right: Recommendations for Developing User
28 Instructions for Medical Devices Used in Home Health
29 Care," Department of Health and Human Services,
30 Publication No. FDA 93-4258, 1993.

31 8. Mettger, W., and J. Mara, "Clear & Simple:
32 Developing Effective Print Materials for Low-Literate
33 Readers," Bethesda, MD, National Cancer Institute,
34 Publication No. NIH 95-3594, 1994,
35 [http://oc.nci.nih.gov/services/Clear_and_Simple/HOME.h](http://oc.nci.nih.gov/services/Clear_and_Simple/HOME.htm)
36 [tm](http://oc.nci.nih.gov/services/Clear_and_Simple/HOME.htm).

37 9. Silver, N. C., and C. C. Braun, "Perceived
38 Readability of Warning Labels with Varied Font Sizes
39 and Styles," Safety Science, 16:615-625, 1993.

40 10. Wilkins, A. G., and M. I. Nimmo-Smith, "The
41 Clarity and Comfort of Printed Text," Ergonomics,
42 30:1705-1720, 1987.

43 11. Transcript of public meeting on prescription
44 drug labeling, Docket No. 95N-0314, October 30, 1995.

45 12. Eastern Research Group, Inc., "Cost Impacts
46 of the Over-the-Counter Pharmaceutical Labeling Rule,"
appendix A, March 5, 1999.

48 13. Connelly, D. P. et al., "Knowledge Resource
49 Preferences of Family Physicians," Journal of Family
50 Practice, 31(2):121-122, 1990.

51 14. Ely, J. W. et al., "What Clinical
52 Information Resources Are Available in Family
53 Physicians' Offices?" Journal of Family Practice,
54 48(2):135-139, 1999.

55 15. Ely, J. W. et al., "The Information Needs of
56 Family Physicians: Case-Specific Clinical Questions,"
57 Journal of Family Practice, 35(3):265-269, 1992.

58 16. Gorman, P., "Information Needs in Primary
59 Care: A Survey of Rural and Nonrural Primary Care
60 Physicians," Medinfo, 10(Pt. 1):338-342, 2001.

61 17. National Association of Chain Drug Stores,
62 "Industry Facts-at-a-Glance--Rx Sales 2001,"
63 <http://www.nacds.org/wmepage.cfm?parml=507#rx> (last
64 viewed 8/27/02).

65 18. U.S. Department of Labor, Bureau of Labor
66 Statistics, "2000 National Occupational Employment and
67 Wage Estimates--29-1051 Pharmacists,"
68 <http://www.bls.gov/oes/2000/oes291051.htm> (last viewed
69 8/27/02).

70 19. U.S. Department of Labor, Bureau of Labor
71 Statistics, Occupational Outlook Handbook, 2002-03,

72 Pharmacists (occupation code 29-1051), 2002,
73 <http://www.bls.gov/oco/ocos079.htm> (last viewed
74 9/13/02).

75 20. Jousimaa, J. et al., "Physicians' Patterns
76 of Using a Computerized Collection of Guidelines for
77 Primary Care," International Journal of Technology
78 Assessment in Health Care, 14(3):484-493, 1998.

79 21. U.S. Census Bureau, "Table 153, Physicians
80 by Selected Activity: 1980 to 1999," Statistical
81 Abstract of the United States: 2001, p. 106.

82 22. U.S. Census Bureau, "Table 157, Medical
83 Practice Characteristics by Selected Specialty: 1985
84 to 1998," Statistical Abstract of the United States:
85 2001, p. 108.

86 23. American Medical Association, "Medical
87 Education FAQs," [http://www.ama-
89 assn.org/ama/pub/category/3627.html](http://www.ama-
88 assn.org/ama/pub/category/3627.html) (last viewed
90 9/13/02).

91 24. Woosley, R. L., "Drug Labeling Revisions--
92 Guaranteed to Fail?" Journal of the American Medical
93 Association, 284(23):3047-3049, 2000.

94 25. Friedman, M. A. et al., "The Safety of Newly
Approved Medicines: Do Recent Market Removals Mean

05 There Is a Problem?" Journal of the American Medical
96 Association, 281(18):1728-1734, 1999.

97 26. U.S. General Accounting Office, "Adverse
98 Drug Events: The Magnitude of Health Risk Is Uncertain
99 Because of Limited Incidence Data," GAO/HEHS-00-21,
100 January, 2000.

101 27. Bates, D. W. et al., "Incidence of Adverse
102 Drug Events and Potential Adverse Drug Events,"
103 Journal of the American Medical Association,
104 274(1):29-34, 1995.

105 28. Classen, D. C. et al., "Adverse Drug Events
106 in Hospitalized Patients: Excess Length of Stay,
107 Extra Costs, and Attributable Mortality," Journal of
108 the American Medical Association, 277(4):301-306,
109 1997.

110 29. Senst, B. L. et al., "Practical Approach to
111 Determining Costs and Frequency of Adverse Drug Events
112 in a Health Care Network," American Journal of Health-
113 Systems Pharmacy, 58:1126-1132, 2001.

114 30. 2000 hospital discharges data from the
115 Agency for Health Care Policy and Research (AHCPR),
116 June 25, 1998, <http://www.ahrq.gov/HCUPnet.htm> (last
117 viewed 8/13/02).

118 31. Bates, D. W. et al., "The Costs of Adverse
119 Drug Events in Hospitalized Patients," Journal of the
120 American Medical Association, 277(4):307-311, 1997.

121 32. Medical Group Management Association, AHRQ,
122 CMS and Partnership for Patient Safety, "Ambulatory
123 Patient Safety: What Do We Know?" An Agenda for
124 Research in Ambulatory Patient Safety--Synthesis of a
125 Multidisciplinary Conference, 2000,
126 <http://www.ahcpr.gov/about/cpcr/ptsafety/ambpts2.htm>
127 (last viewed 10/10/02).

128 33. Thomas, E. J. et al., "Costs of Medical
129 Injuries in Utah and Colorado," Inquiry, 36:255-264,
130 1999.

131 34. Johnson, J. A., and J. L. Bootman, "Drug-
132 Related Morbidity and Mortality: A Cost-of-Illness
133 Model," Archives of Internal Medicine, 155:1949-1956,
134 1995.

135 35. Ernst, F. R., and A. J. Grizzle, "Drug-
136 Related Morbidity and Mortality: Updating the Cost-
137 of-Illness Model," Journal of the American
138 Pharmaceutical Association, 41(2):192-199, 2001.

139 36. IMS Health, "Product Sampling Continues
140 to Spike in U.S.," 2001,

141 [http://www.imshealth.com/public/structure/discontent/](http://www.imshealth.com/public/structure/discontent/1,2779,1362-1362-143626,00.html)
142 [1,2779,1362-1362-143626,00.html](http://www.imshealth.com/public/structure/discontent/1,2779,1362-1362-143626,00.html) (last viewed 9/23/02).

143 37. U.S. Census Bureau, "Statistics of U.S.
144 Businesses; 1999; Pharmaceutical preparation mfg,
145 United States,"

146 <http://www.census.gov/epcd/susb/1999/us/US325412.htm>
147 (last viewed 9/12/02).

148 38. U.S. Census Bureau, "Statistics of U.S.
149 Businesses; 1999; Biological product (except
150 diagnostic) mfg, United States,"

151 <http://www.census.gov/epcd/susb/1999/us/US325414.htm>
152 (last viewed 9/12/02).

153